Now Medilinks Inc has become Advance Medilinks Private Limited

Welcome to Medilinks

Medilinks Inc is a facilitator of specialized Genomic and Genetic testing’s which help and guide
Physicians during patients treatment. Medilinks Inc founded in 2007.

The only genomic test proven to predict a patient’s individual benefit from chemotherapy. For patients with early-stage, ER-positive, HER2-negative, node negative, and node-positive (1-3) breast cancer, the Oncotype DX Breast Recurrence Score quantifies the risk of distant recurrence and the likelihood of chemotherapy benefit.

The only genomic test to quantify the risk of local recurrence (DCIS or invasive) in ductal carcinoma in situ. For patients with ductal carcinoma in situ (DCIS) treated by local excision, with or without tamoxifen, the Oncotype DX Breast DCIS Score can help guide personalized treatment decisions.




A genomic test that quantifies the risk of recurrence, for insight beyond traditional measures. For patients with stage II or II A/B colon cancer whose tumor has been resected, the Oncotype DX Colon Recurrence score can help guide decisions about adjuvant treatment.




We constantly strive to anticipate the aspiration
of our consumer and respond creatively With branded products

CONTACT US

Medilinks Inc is a facilitator of specialized Genomic and Genetic testing’s which help and guide Physicians during patients treatment.

FX-A-2901, Marathon Futurex, Mafatlal Mills Compound, N. M. Joshi Marg, Lower Parel, Mumbai - 400013.

Menu